• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8/6/24 9:05:17 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email
    false 0001269026 0001269026 2024-07-31 2024-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): July 31, 2024

     

    SINTX Technologies, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33624   84-1375299

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1885 West 2100 South

    Salt Lake City, UT 84119

    (Address of principal executive offices, including Zip Code)

     

    Registrant’s telephone number, including area code: (801) 839-3500

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol(s):   Name of each exchange on which registered:
    Common Stock, par value $0.01 per share   SINT   The NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On July 31, 2024, the Board of Directors of SINTX Technologies, Inc. (the “Company”) appointed Eric K. Olson as Chief Executive Officer and President with such appointment effective August 1, 2024.

     

    Prior to being appointed as Chief Executive Officer and President, from June 2022 to August 2024, Mr. Olson, age 61, served as Founder, Chief Executive Officer and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. From January 2016 to June 2022, Mr. Olson was the founder, President, Chief Executive Officer and Board Member of Predictive Biotech, Inc., which developed the first human stem cell and tissue product (HCT/P) derived from the perinatal tissue. Prior to joining Predictive Biotech, Mr. Olson was the President and Chief Executive Officer for Cupertino based Skeletal Kinetics from December 2014 to January 2016. This Colson & Associates company developed and commercialized synthetic bone substitute products for Orthopedic and Spinal applications. From February 2012 to September 2014, Mr. Olson served as Chief Executive Officer and President and a member of the board of directors of SINTX Technologies (formerly Amedica Corporation). Mr. Olson began his career with London-based Smith & Nephew and has worked in Senior Sales and Marketing leadership roles with Johnson & Johnson, Medtronic and Wright Medical. He earned Bachelor of Science Degrees in Behavioral Science and Health Administration from The University of Utah and completed a Master’s level Hospital Administration Internship Program at the same institution.

     

    There are no family relationships between Mr. Olson and any director or other executive officer of the Company. There are no transactions to which the Company was or is a participant and in which Mr. Olson has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

     

    There are no arrangements or understandings between Mr. Olson and any other person pursuant to which he was selected as an officer of the Company.

     

    In connection with Mr. Olson’s appointment, B. Sonny Bal retired from his position as Chief Executive Officer and President and now serves as Chairman of the Board.

     

    Item 8.01 Other Events.

     

    On August 6, 2024, the Company issued a press release announcing the appointment of Eric K. Olson as Chief Executive Officer. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit No.   Description
         
    99.1   Press release dated August 6, 2024.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        SINTX Technologies, Inc.
           
    Date: August 6, 2024   By: /s/ Eric K. Olson
          Eric K. Olson
          Chief Executive Officer

     

     

     

    Get the next $SINT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    SEC Filings

    See more
    • SiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sintx Technologies, Inc. (0001269026) (Filer)

      5/22/25 7:15:34 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SiNtx Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sintx Technologies, Inc. (0001269026) (Filer)

      5/15/25 7:10:20 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by SiNtx Technologies Inc.

      10-Q - Sintx Technologies, Inc. (0001269026) (Filer)

      5/15/25 7:00:27 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

      SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

      11/14/24 7:25:52 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by SiNtx Technologies Inc.

      SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

      4/1/24 4:17:43 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by SiNtx Technologies Inc. (Amendment)

      SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

      2/13/24 8:12:54 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market

      SALT LAKE CITY, Utah, May 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramics for medical device and other technical applications, announced the issuance of International Patent No. 7635292, which covers novel agricultural uses of the Company's silicon nitride (Si₃N₄) particularly in plant protection and antimicrobial treatment. This patent, combined with issued U.S. Patent No. 11,591,217, creates a family of patents focused on addressing the antimicrobial agribiotech market. SINTX remains focused on advancing silicon nitride technologies for medical applications; however, the material's broad utility allows for sel

      5/22/25 7:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization

      Salt Lake City, UT , May 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT), an advanced ceramics company pioneering medical and antipathogenic applications of silicon nitride (Si₃N₄), today provided a comprehensive update on its operational progress, strategic initiatives, and financial position for the first quarter ended March 31, 2025. "We are executing a disciplined transformation that aligns our core capabilities in advanced ceramics with fast-growing, high-impact healthcare applications. This transition positions us for sustainable value creation," said Eric K. Olson, CEO and President of SINTX Technologies. Refocusing on High-Growth Medical Markets SINTX has ac

      5/15/25 7:05:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Announces Strategic Changes to Board of Directors

      Company positions for long-term growth in medical device markets Salt Lake City, UT, April 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT), an advanced ceramics company focused on medical device applications, today announced changes to its Board of Directors. The updates reflect the Company's ongoing strategic transformation into a focused medical technology business. Key changes include the retirement of longtime Chairman Dr. B. Sonny Bal, the appointment of President and CEO Eric Olson as Chairman of the Board, and the addition of five new directors with decades of industry expertise spanning orthopedics, spine, interventional pain, cardiovascular, medical device bu

      4/3/25 8:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Mark Lewis bought $11,800 worth of shares (5,000 units at $2.36) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/14/25 7:00:09 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • Chief Strategy Officer Honigblum Gregg R. bought $7,160 worth of shares (4,000 units at $1.79), increasing direct ownership by 40% to 14,000 units (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/1/25 6:10:49 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • President and CEO Olson Eric K. bought $28,088 worth of shares (14,500 units at $1.94) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      4/30/25 2:25:41 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Financials

    Live finance-specific insights

    See more

    $SINT
    Leadership Updates

    Live Leadership Updates

    See more
    • SINTX Technologies Acquires Technology Assessment and Transfer, Inc.

      The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno

      7/6/22 9:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Issues 2022 10-K and Announces Investor Conference Call

      SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced today the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission. In 2021, SINTX made significant investments into the expansion of its three priority business segments - biomedical, industrial/armor, and antipathogenic - through the purchase of new technology, equipment, and personnel. The Company is narrowly focused on opportunities closest to revenue such as armor materials and plates, the development of new biomedi

      3/25/22 5:41:39 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

      SALT LAKE CITY, June 30, 2021 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced today it has moved into the next phase of its relationship with O2TODAY and sold the first shipment of FleX SN-AP antipathogenic silicon nitride powder to O2TODAY for integration into a proprietary line of masks and filters. "O2TODAY announced on its website today that it is taking limited pre-orders for masks and mask filters integrated with SINTX's antipathogenic powder," said Dr. Sonny Bal, President and CEO at SINTX Technologies. "We share th

      6/30/21 9:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

      Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

      11/19/24 6:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Mark Lewis bought $11,800 worth of shares (5,000 units at $2.36) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/14/25 7:00:09 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • Chief Strategy Officer Honigblum Gregg R. bought $7,160 worth of shares (4,000 units at $1.79), increasing direct ownership by 40% to 14,000 units (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/1/25 6:10:49 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • President and CEO Olson Eric K. bought $28,088 worth of shares (14,500 units at $1.94) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      4/30/25 2:25:41 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care